Pacira BioSciences, Inc. (NASDAQ:PCRX) Stock Position Lowered by Rice Hall James & Associates LLC

Rice Hall James & Associates LLC decreased its position in Pacira BioSciences, Inc. (NASDAQ:PCRX) by 3.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 260,185 shares of the company’s stock after selling 8,152 shares during the quarter. Rice Hall James & Associates LLC owned about 0.56% of Pacira BioSciences worth $4,902,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Pacer Advisors Inc. lifted its holdings in Pacira BioSciences by 129.4% in the 3rd quarter. Pacer Advisors Inc. now owns 4,962,221 shares of the company’s stock valued at $74,681,000 after acquiring an additional 2,799,434 shares during the last quarter. State Street Corp lifted its stake in Pacira BioSciences by 5.8% during the third quarter. State Street Corp now owns 2,014,012 shares of the company’s stock valued at $30,311,000 after purchasing an additional 110,162 shares during the last quarter. Assenagon Asset Management S.A. boosted its holdings in Pacira BioSciences by 314.4% during the third quarter. Assenagon Asset Management S.A. now owns 553,114 shares of the company’s stock worth $8,324,000 after buying an additional 419,656 shares in the last quarter. Impax Asset Management Group plc grew its position in Pacira BioSciences by 81.0% in the third quarter. Impax Asset Management Group plc now owns 470,603 shares of the company’s stock worth $7,083,000 after buying an additional 210,576 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. grew its position in Pacira BioSciences by 4.1% in the third quarter. Charles Schwab Investment Management Inc. now owns 431,897 shares of the company’s stock worth $6,500,000 after buying an additional 16,819 shares during the last quarter. 99.73% of the stock is owned by institutional investors and hedge funds.

Pacira BioSciences Price Performance

Shares of PCRX opened at $25.44 on Tuesday. Pacira BioSciences, Inc. has a 52 week low of $11.16 and a 52 week high of $31.67. The company has a quick ratio of 1.89, a current ratio of 2.25 and a debt-to-equity ratio of 0.51. The company’s 50 day moving average price is $22.00 and its 200 day moving average price is $18.13.

Analyst Ratings Changes

PCRX has been the subject of several research reports. HC Wainwright reissued a “buy” rating and set a $39.00 price objective on shares of Pacira BioSciences in a research note on Wednesday, December 4th. Truist Financial upgraded Pacira BioSciences from a “sell” rating to a “hold” rating and increased their price target for the company from $8.00 to $25.00 in a research report on Thursday, January 30th. Needham & Company LLC boosted their price objective on Pacira BioSciences from $22.00 to $30.00 and gave the stock a “buy” rating in a report on Monday, January 13th. Royal Bank of Canada reiterated a “sector perform” rating and issued a $18.00 target price on shares of Pacira BioSciences in a report on Tuesday, January 14th. Finally, Barclays cut their price target on shares of Pacira BioSciences from $25.00 to $17.00 and set an “equal weight” rating on the stock in a report on Tuesday, November 12th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and four have issued a buy rating to the stock. According to MarketBeat, Pacira BioSciences currently has an average rating of “Hold” and a consensus price target of $22.78.

Pacira BioSciences Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.